intern
meet
bordetella
pertussi
assay
standard
harmon
held
center
diseas
control
prevent
cdc
atlanta
ga
juli
goal
meet
harmon
immunoassay
use
pertussi
diagnost
vaccin
evalu
agre
upon
academ
govern
research
regulatori
author
vaccin
manufactur
world
health
organ
primari
object
provid
epidemiolog
laboratori
statist
background
support
global
harmon
overview
current
statu
global
epidemiolog
pathogenesi
immunolog
pertussi
develop
consensu
opinion
exist
gap
understand
standard
pertussi
assay
use
serodiagnosi
vaccin
evalu
search
multicent
process
address
prioriti
gap
present
discuss
content
expert
address
object
priorit
list
action
item
improv
standard
harmon
pertussi
assay
identifi
group
discuss
end
meet
major
item
includ
identifi
group
organ
prepar
maintain
distribut
profici
panel
key
reagent
refer
control
sera
encourag
develop
identif
one
refer
laboratori
serv
anchor
resourc
laboratori
defin
performancebas
assay
method
serv
refer
point
evalu
laboratori
differ
develop
guidanc
qualiti
reagent
eg
pertussi
toxin
antigen
method
demonstr
suitabl
establish
intern
work
group
harmon
criteria
evalu
result
obtain
refer
profici
panel
sera
creat
inventori
determin
amount
appropri
wellcharacter
sera
avail
global
use
bridg
reagent
vaccin
licensur
seek
specif
guidanc
regulatori
author
regard
expect
requir
licensur
new
multicompon
pertussi
vaccin
pertussi
whoop
cough
highli
contagi
acut
respiratori
ill
caus
bacteri
pathogen
bordetella
pertussi
despit
high
vaccin
coverag
pertussi
continu
major
caus
morbid
mortal
unit
state
probabl
confirm
case
report
respect
among
report
bacteri
vaccineprevent
diseas
unit
state
univers
childhood
vaccin
pertussi
least
well
control
pertussi
also
remain
substanti
public
health
problem
develop
region
european
union
canada
studi
suggest
approxim
find
conclus
report
author
section
necessarili
repres
entir
group
particip
offici
posit
center
diseas
control
preventionag
toxic
substanc
diseas
registri
find
conclus
report
formal
dissemin
us
food
drug
administr
constru
repres
agenc
determin
polici
lion
annual
case
pertussi
worldwid
death
howev
total
burden
pertussi
like
underestim
especi
among
adolesc
adult
typic
pertussi
symptom
often
absent
make
diagnosi
difficult
laboratori
diagnosi
pertussi
challeng
cultur
highli
specif
requir
long
incub
sensit
low
rapid
sensit
specif
polymeras
chain
reaction
pcr
assay
design
detect
b
pertussi
howev
assay
well
standard
problem
occur
specif
mainli
outbreak
serolog
test
b
pertussi
antigen
pertussi
toxin
pt
particular
sensit
specif
test
wide
avail
fulli
standard
univers
accept
serolog
correl
protect
avail
meet
session
cover
follow
topic
global
epidemiolog
b
pertussi
diseas
pathogenesi
immunolog
b
pertussi
assay
standard
harmon
serodiagnosi
b
pertussi
current
futur
b
pertussi
vaccin
composit
issu
vaccin
evalu
perspect
regulatori
author
vaccin
manufactur
group
discuss
includ
serodiagnost
vaccin
evalu
correl
protect
harmon
assay
list
action
item
develop
identifi
exist
knowledg
gap
coordin
intern
effort
standard
pertussi
assay
immunolog
diagnost
use
meet
open
lucia
tondella
phd
cdc
follow
nanci
messonni
md
cdc
stress
import
laboratori
epidemiolog
statist
group
work
togeth
facilit
support
global
harmon
dr
messonni
also
highlight
necess
improv
pertussi
diagnost
point
alon
cdc
experienc
numer
occas
problem
diagnost
imped
epidemiolog
investig
result
substanti
public
health
outcri
cdc
mening
vaccin
prevent
diseas
branch
extens
experi
work
standard
harmon
assay
varieti
organ
experi
brought
bear
meet
determin
current
statu
pertussi
serolog
technolog
key
laboratori
facilit
discuss
key
issu
pertussi
serolog
establish
consensu
action
plan
need
address
issu
present
discuss
summar
present
jame
cherri
md
david
geffen
school
medicin
univers
california
lo
angel
nicol
guiso
phd
institut
pasteur
pari
franc
prevaccin
era
unit
state
pertussi
diseas
cyclic
peak
averag
everi
year
averag
rate
report
case
per
popul
report
case
occur
children
younger
year
age
pertussi
well
control
immun
case
report
per
year
case
occur
infant
present
pertussi
report
case
person
older
year
age
sinc
modest
increas
report
pertussi
case
per
popul
recent
year
report
increas
consider
howev
number
case
still
approxim
less
prevaccin
era
cycl
report
pertussi
today
essenti
prevaccin
era
examin
report
pertussi
sever
countri
present
found
two
differ
pattern
countri
argentina
bangladesh
bolivia
brazil
cambodia
ghana
pakistan
peru
sudan
vietnam
reduct
total
case
similar
seen
unit
state
similar
pattern
also
note
unit
kingdom
pertussi
reason
well
control
vaccin
earli
concern
vaccin
safeti
result
mark
declin
immun
pertussi
becam
epidem
brought
control
earli
increas
vaccin
usag
itali
vaccin
consist
offer
efficaci
trial
mark
reduct
pertussi
relat
use
diphtheria
tetanu
toxoid
acellular
pertussi
compon
dtap
vaccin
success
control
report
pertussi
countri
except
itali
secondari
use
dose
dtwp
wholecel
vaccin
first
year
life
franc
high
vaccin
coverag
among
children
dtwp
vaccin
last
year
pertussi
predominantli
affect
children
young
vaccin
adult
longer
protect
vaccin
diseaseinduc
immun
survey
undertaken
pediatr
hospit
network
demonstr
increas
number
children
hospit
pertussi
suggest
import
introduc
booster
dose
prolong
vaccin
immun
reduc
exposur
b
pertussi
infant
young
immun
therefor
fifth
dose
acellular
pertussi
ap
vaccin
introduc
old
follow
introduct
socal
cocoon
strategi
current
vaccin
schedul
consist
primari
immun
children
age
month
booster
month
year
old
young
adult
healthcar
worker
contact
infant
dtwp
vaccin
commerci
avail
sinc
nation
hospitalbas
surveil
renacoq
network
shown
resurg
pertussi
observ
countri
cycl
diseas
occur
everi
year
howev
number
pertussi
case
reach
valu
observ
earlier
peak
year
could
link
impact
booster
introduc
year
previous
report
pertussi
case
australia
chile
israel
japan
norway
poland
increas
recent
year
australia
israel
norway
increas
follow
introduct
dtap
vaccin
possibl
reason
resurg
report
pertussi
greater
awar
pertussi
wane
vaccineinduc
immun
lessen
potenc
pertussi
vaccin
genet
chang
b
pertussi
gener
avail
better
laboratori
test
diagnosi
pertussi
import
gener
greater
awar
pertussi
avail
better
laboratori
test
pcr
singleserum
serolog
diagnos
adolesc
adult
pertussi
also
contribut
increas
report
case
evid
also
suggest
gener
dtap
vaccin
may
less
efficaci
children
potent
dtwp
vaccin
plausibl
decreas
efficaci
durat
protect
could
possibl
contribut
outbreak
seen
preadolesc
adolesc
investig
unit
state
area
world
use
variou
laboratori
method
diagnos
pertussi
subject
prolong
cough
ill
one
commonli
use
diagnost
marker
high
singleserum
titer
pt
result
studi
suggest
prolong
cough
ill
due
b
pertussi
infect
howev
adult
pt
antibodi
respons
follow
infect
percentag
like
higher
summari
b
pertussi
infect
adolesc
adult
common
rate
report
pertussi
may
much
lower
actual
ill
rate
unrecogn
infect
eg
asymptomat
nonspecif
symptom
like
common
symptomat
infect
today
symptomat
adolesc
adult
appear
major
sourc
infect
nonvaccin
children
much
discuss
relat
epidemiolog
focus
increas
pertussi
recent
year
despit
adequ
increas
vaccin
use
young
children
gener
like
caus
thought
greater
awar
pertussi
howev
data
australia
present
later
meet
suggest
falseposit
laboratori
test
contribut
increas
report
pertussi
least
one
set
discuss
includ
possibl
instanc
genet
chang
pertussi
organ
may
contribut
increas
countri
use
dtwp
chang
vaccin
manufactur
even
lot
may
signific
relationship
efficaci
increas
observ
pertussi
associ
introduct
acellular
vaccin
studi
care
present
erik
l
hewlett
md
univers
virginia
school
medicin
charlottesvil
virginia
multipl
virul
factor
produc
b
pertussi
abl
disrupt
normal
physiolog
host
caus
diseas
pertussi
diseas
consist
local
infect
respiratori
tract
secondari
system
effect
result
action
sever
bacteri
product
host
respons
factor
molecular
basi
characterist
paroxysm
cough
known
mimick
intraven
pt
one
like
role
pt
impair
innat
immun
respons
host
caus
leukolymphocytosi
block
migrat
murin
macrophag
reduc
express
lselectin
surfac
leukocyt
infant
infect
b
pertussi
also
demonstr
leukolymphocytosi
sever
effect
pt
mediat
adpribosyl
transferas
activ
catalyt
domain
pt
bind
receptor
elicit
separ
set
respons
known
bsubunit
effect
recent
shown
pt
bsubunit
activ
signal
tcell
receptor
without
contribut
adpribosyl
similarli
pt
enzymat
inact
nonadpribosyl
mutant
stimul
cytokin
product
dendrit
cell
matur
evid
indic
multipl
virul
factor
b
pertussi
immunomodulatori
effect
sever
instanc
effect
appear
antagonist
one
anoth
exampl
shown
filament
hemagglutinin
fha
proinflammatori
abl
induc
apoptosi
macrophag
similarli
adenyl
cyclas
toxin
act
known
inhibitori
effect
cytotox
neutrophil
phagocyt
cell
also
proinflammatori
effect
induc
respiratori
epitheli
cell
cell
express
integrin
diseas
process
pertussi
appear
multifactori
rather
function
singl
toxinvirul
factor
therefor
ideal
immunolog
respons
host
consist
antibodi
direct
multipl
virul
factor
result
inhibit
bacteri
adher
neutral
action
toxin
clearanc
infect
organ
addit
cellmedi
compon
host
respons
immun
infect
studi
relev
target
antigen
cellular
respons
direct
contribut
make
bacteri
clearanc
unknown
sever
major
issu
pertussi
pathogenesi
remain
unresolv
despit
numer
known
biolog
effect
individu
virul
factor
especi
vitro
vivo
target
tissu
molecul
mechan
characterist
cough
gener
mysteri
molecular
detail
bvg
twocompon
regulatori
system
control
product
virul
factor
known
summari
pertussi
multicompon
diseas
requir
simpl
approach
recognit
treatment
control
recent
analys
effect
known
toxin
virul
factor
immun
system
reveal
often
multifunct
cytotox
stimulatori
inhibitori
proand
antiinflammatori
much
discuss
focus
potenti
neurophysiolog
effect
multipl
virul
factor
anim
model
includ
new
method
infect
inhal
techniqu
novel
imag
analysi
could
help
understand
pathogenesi
pertussi
human
recent
research
studi
shown
presenc
b
pertussi
dna
clinic
specimen
children
sever
month
infect
possibl
remain
dna
could
trigger
cough
unrecogn
mechan
specul
present
kathryn
edward
md
vanderbilt
medic
center
nashvil
tennesse
standard
harmon
necessari
sever
reason
assess
immunogen
new
pertussi
vaccin
new
combin
vaccin
includ
pertussi
antigen
compar
serolog
respons
new
vaccin
evalu
earlier
vaccin
efficaci
studi
purpos
vaccin
licensur
establish
serolog
criteria
clinic
diagnosi
pertussi
diseas
conduct
seroepidemiolog
studi
assess
circul
pattern
pertussi
commun
multipl
ap
vaccin
licens
use
infant
adolesc
adult
combin
vaccin
incorpor
variou
antigen
singl
inject
design
combin
vaccin
may
associ
reduc
serolog
respons
one
vaccin
antigen
therefor
antibodi
titer
induc
product
must
compar
seen
separ
administr
individu
vaccin
combin
vaccin
consid
licensur
safeti
immunogen
ap
two
dtwp
vaccin
assess
singl
larg
clinic
trial
although
trial
evalu
differ
pertussi
antigen
administ
variou
concentr
vaccin
found
safe
immunogen
sever
vaccin
evalu
efficaci
trial
european
union
africa
found
efficaci
prevent
cultureconfirm
pertussi
sinc
placebocontrol
efficaci
trial
would
consid
uneth
new
vaccin
must
evalu
comparison
immunogen
data
vaccin
evalu
earlier
efficaci
trial
thu
need
standard
assay
critic
standard
serolog
assay
also
need
diagnos
pertussi
diseas
particularli
adolesc
adult
studi
conduct
determin
populationbas
antibodi
level
three
pertussi
antigen
pt
fha
fimbrial
protein
fim
purpos
establish
diagnost
cutoff
point
adolesc
adult
unit
state
enzymelink
immunosorb
assay
elisa
perform
sera
us
resid
age
year
quantifi
elisa
unit
eu
ml
antifha
antifim
igg
antibodi
common
quantifi
antipt
igg
antibodi
less
frequent
antipt
igg
level
eu
propos
diagnost
cutoff
point
subject
year
age
older
applic
cutoff
point
cultureconfirm
ill
yield
high
diagnost
sensit
specif
antipt
igg
assay
singl
serum
sampl
appear
use
identif
recent
b
pertussi
infect
adolesc
adult
howev
assay
must
standard
remain
use
diagnosi
pertussi
final
standard
serolog
method
b
pertussi
need
assess
epidemiolog
trend
pertussi
diseas
popul
particularli
relev
univers
recommend
adolesc
adult
pertussi
vaccin
mani
develop
countri
univers
vaccin
affect
diseas
burden
variou
age
group
remain
determin
addit
comparison
seroepidemiolog
result
one
countri
anoth
depend
standard
assay
present
bruce
mead
phd
mead
biolog
llc
hillsborough
nc
dorothi
xing
phd
nation
institut
biolog
standard
control
nibsc
potter
bar
uk
anna
giammanco
phd
depart
hygien
microbiolog
univers
palermo
itali
import
insight
strategi
intern
standard
pertussi
immunoassay
provid
result
intern
collabor
studi
perform
studi
particip
laboratori
ask
quantifi
specif
antibodi
pt
fha
pertactin
prn
fim
panel
blind
sampl
use
elisa
routin
perform
laboratori
laboratori
employ
varieti
procedur
antigen
conjug
reagent
calcul
method
result
indic
overal
consist
among
laboratori
reason
quantit
agreement
achiev
among
laboratori
assay
calibr
use
us
refer
pertussi
antisera
agreement
demonstr
use
common
refer
serum
success
harmon
result
promot
higher
level
intern
standard
pertussi
immunoassay
highest
prioriti
recommend
would
improv
avail
refer
reagent
method
includ
intern
refer
sera
profici
panel
wellcharacter
sera
wellcharacter
antigen
recent
year
signific
progress
prepar
standard
intern
refer
sera
made
collabor
studi
evalu
propos
intern
refer
prepar
pertussi
antiserum
human
multicent
collabor
nibsc
uk
center
biolog
evalu
research
cber
food
drug
administr
fda
us
institut
infektiologi
ifi
germani
number
intern
particip
refer
sera
unit
state
us
refer
pertussi
antiserum
human
lot
lot
iggantibodi
lot
igaantibodi
prepar
fda
cber
year
ago
sinc
commonli
use
refer
standard
pertussi
serolog
assay
current
limit
quantiti
sera
remain
increas
number
vaccin
diagnost
studi
wide
avail
intern
standard
prepar
need
ad
hoc
pertussi
work
group
recommend
prepar
standard
intern
human
refer
antiserum
pertussi
antigen
replac
current
wide
use
cber
prepar
suppli
exhaust
agre
far
possibl
continu
exist
cber
refer
prepar
maintain
new
intern
refer
materi
intend
follow
use
vaccin
studi
product
current
distribut
well
develop
studi
serolog
respons
infect
epidemiolog
surveil
futur
assess
antibodi
antigen
apart
pt
fha
prn
evalu
new
gener
vaccin
serum
pool
kindli
donat
dr
wirs
von
ifi
krefeld
germani
prepar
recalcif
plasma
sampl
select
blood
bank
pertussi
outbreak
germani
sera
lyophil
nibsc
result
four
batch
freezedri
prepar
ampoul
higher
titer
ampoul
lower
titer
iggantipt
preliminari
assess
freezedri
materi
nibsc
show
comparison
materi
freezedri
freezedri
materi
maintain
origin
elisa
bind
activ
furthermor
comparison
candid
materi
us
refer
sera
show
doserespons
line
deviat
significantli
parallel
intern
collabor
studi
evalu
candid
prepar
initi
march
aim
studi
character
candid
intern
refer
prepar
pertussi
antiserum
human
compar
candid
refer
us
refer
prepar
lot
compar
candid
refer
prepar
avail
refer
prepar
eg
inhous
prepar
defin
unitag
candid
prepar
antipt
antifha
antiprn
maintain
continu
wide
use
refer
prepar
sampl
provid
particip
four
candid
refer
prepar
three
us
refer
sera
plu
neg
control
serum
particip
quest
carri
three
independ
assay
igg
antipt
fha
prn
elisa
use
methodolog
reagent
calcul
method
includ
inhous
refer
control
particip
also
encourag
perform
assay
could
interest
eg
igg
antifim
iga
antibodi
antigen
ptneutral
antibodi
chocel
assay
total
laboratori
worldwid
particip
studi
includ
europ
north
america
south
america
laboratori
asia
australia
particip
request
submit
raw
result
nibsc
statist
analysi
perform
studi
report
submit
expert
committe
biolog
standard
ecb
anoth
multilaboratori
effort
standard
pertussi
serolog
assay
european
seroepidemiolog
network
esen
project
coordin
health
protect
agenc
hpa
communic
diseas
surveil
center
cdsc
london
aim
esen
project
coordin
harmon
serolog
surveil
varieti
infect
europ
agestratifi
serum
bank
recommend
sampl
size
individu
collect
particip
countri
one
laboratori
select
serv
refer
laboratori
diseas
laboratori
test
sera
countri
plu
share
panel
approxim
serum
sampl
standard
process
allow
comparison
nation
serosurvey
pertussi
difficulti
standard
cell
extract
esen
project
emphas
purifi
antigen
focus
igg
antipt
assay
higher
sensit
specif
serodiagnosi
sinc
individu
expos
pertussi
vaccin
infect
studi
focus
estim
incid
recent
infect
defin
presenc
igg
antipt
antibodi
defin
threshold
accomplish
quantit
assay
requir
standard
effort
base
analyt
perform
assay
rang
near
diagnost
threshold
conclus
esen
project
demonstr
standard
pertussi
igg
antipt
assay
possibl
appropri
applic
diagnost
laboratori
test
requir
understand
test
well
knowledg
patient
relev
criteria
test
includ
test
format
specif
sensit
refer
system
clinic
interpret
test
result
concern
b
pertussi
infect
also
requir
understand
distinct
primari
secondari
infect
differenti
diagnos
includ
agent
kinet
immun
respons
infect
understand
inform
provid
test
beyond
provid
clinic
histori
alon
perform
laboratori
test
display
cutoff
valu
shown
reporteroper
characterist
roc
curv
well
posit
neg
predict
valu
differenti
diagnosi
b
pertussi
agent
prolong
cough
includ
infecti
agent
adenoviru
respiratori
syncyti
viru
rhinoviru
human
parainfluenzaviru
influenzaviru
b
mycoplasma
pneumonia
human
metapneumoviru
human
coronaviru
sever
altern
approach
use
serodiagnosi
pair
sera
use
one
studi
defin
case
increas
antibodi
concentr
decreas
antibodi
concentr
singlesampl
serolog
variou
cutoffvalu
propos
euml
iggantipt
netherland
euml
iggantipt
iggantipt
euml
igaantifha
germani
diagnost
laboratori
socal
greyzon
defin
sera
posit
specifi
threshold
diagnost
cutoff
greyzon
set
netherland
sweden
euml
iggantipt
sensit
specif
singlesampl
serolog
assay
determin
one
studi
done
popul
children
year
age
mostli
nonvaccin
germani
use
cutoff
euml
percentil
popul
specif
sensit
found
increas
igaantifha
ad
anoth
studi
done
without
age
limit
mostli
vaccin
popul
netherland
use
cutoff
euml
percentil
popul
studi
found
sensit
wherea
cutoff
euml
percentil
popul
sensit
recent
german
studi
evalu
person
hospit
depart
pediatrician
offic
childcar
facil
receiv
one
inject
ap
vaccin
inform
consent
blood
sampl
vaccin
month
year
year
year
year
vaccin
iggand
igaantibodi
pt
fha
iggantiprn
measur
popul
distribut
igg
antipt
level
prior
immun
examin
percentil
euml
percentil
euml
percentil
euml
appli
cutoff
euml
seroepidemiolog
studi
popul
person
age
year
variou
countri
european
union
result
follow
percentag
cohort
show
valu
cutoff
netherland
finland
germani
former
gdr
franc
germani
former
frg
uk
itali
seroepidemiolog
studi
also
demonstr
cyclic
natur
b
pertussi
infect
germani
popul
blood
donor
screen
differ
year
percentag
cohort
iggantipt
euml
follow
diagnost
laboratori
import
defin
custom
use
serolog
inform
specif
use
clinic
decis
patient
manag
use
epidemiolog
studi
similarli
clariti
need
regard
whether
definit
includ
infect
symptomat
infect
infect
medic
resourc
use
sever
infect
diagnost
serolog
also
strongli
influenc
time
patient
seek
medic
attent
rel
onset
symptom
german
studi
perform
among
person
pcrposit
case
median
number
day
cough
seek
medic
attent
found
day
schoolchildren
age
year
day
adolesc
age
year
day
adult
age
year
franc
serolog
test
perform
epidemiolog
studi
surveil
serolog
consist
measur
igg
antipt
antibodi
titer
use
refer
elisa
purifi
pt
provid
manufactur
posit
case
defin
either
twofold
chang
titer
two
serum
sampl
obtain
interv
titer
euml
singl
serum
sampl
serum
collect
week
cough
year
vaccin
booster
french
laboratori
hous
western
blot
assay
use
purifi
pt
well
variou
commerci
test
use
routin
diagnos
assay
valid
also
respons
falseneg
falseposit
result
reason
microbiologist
prefer
realtim
pcr
routin
diagnos
serolog
base
measur
antipt
titer
may
less
use
futur
sinc
children
adolesc
adult
vaccin
ap
vaccin
contain
pt
proport
laboratori
test
perform
diagnos
pertussi
franc
chang
year
accord
renacoq
databas
pertussi
case
diagnos
cultur
pcr
serolog
wherea
case
diagnos
cultur
pcr
serolog
unit
state
massachusett
state
laboratori
institut
use
singleserum
antipt
igg
eia
patient
sampl
sinc
version
current
assay
use
past
includ
measur
iga
igm
pt
igg
fha
antipt
igg
pair
sera
ultim
assay
discontinu
data
indic
contribut
much
addit
inform
beyond
obtain
singl
antipt
igg
alon
plate
coat
commerci
prepar
pt
standard
deriv
pool
posit
patient
sampl
calibr
us
refer
lot
concentr
gml
assign
calcul
fivepoint
standard
dilut
curv
cutoff
point
posit
establish
adult
includ
blood
donor
healthi
volunt
antipt
igg
level
rang
gml
cutoff
point
chosen
base
upper
toler
limit
confid
popul
fall
cutoff
cutoff
point
set
gml
equival
cber
unit
per
ml
actual
quit
high
rel
group
chosen
clinician
ask
order
serolog
assay
patient
older
year
age
cough
present
day
specimen
volum
increas
steadili
last
year
specimen
test
seroposit
fairli
constant
approxim
submit
sampl
mani
challeng
associ
assay
aris
manipul
need
produc
quantit
test
result
may
make
sens
least
massachusett
consid
modif
assay
make
qualit
simpl
robust
abl
perform
consist
accur
less
effort
current
expend
least
two
knowledg
gap
prevent
wider
applic
assay
first
impact
assay
result
adolesc
adult
recent
receiv
tetanu
toxoid
reduc
diphtheria
toxoid
acellular
pertussi
tdap
vaccin
fulli
understood
massachusett
immun
program
contact
everi
seroposit
patient
ask
recent
vaccin
histori
last
year
sinc
tdap
avail
two
seroposit
patient
recent
tdap
vaccin
identifi
one
person
vaccin
day
blood
drawn
serolog
antibodi
detect
unlik
due
vaccin
massachusett
tdapassoci
igg
may
less
problem
origin
anticip
possibl
posttdap
immun
igg
level
frequent
exceed
rel
high
assay
cutoff
valu
altern
clinician
may
submit
sampl
recent
vaccin
recipi
recogn
individu
like
protect
diseas
second
knowledg
gap
uncertain
applic
igg
eia
result
children
younger
year
age
result
consid
uninterpret
age
group
possibl
presenc
vaccineassoci
antibodi
massachusett
state
laboratori
institut
data
seroposit
age
demonstr
peak
seroposit
among
adolesc
young
adult
also
peak
year
age
admittedli
clinic
inform
avail
patient
consid
pertussi
casepati
investig
addit
vaccin
statu
unknown
nevertheless
peak
seroposit
occur
age
may
correspond
fifth
dose
dtap
interestingli
peak
wide
span
year
applic
assay
could
like
extend
age
less
year
australia
experi
use
commerci
serolog
kit
routin
diagnosi
pertussi
iga
use
rather
igg
kit
iga
believ
shortliv
week
comparison
igg
week
children
least
iga
produc
respons
vaccin
unusu
larg
number
pertussi
igaposit
test
report
public
health
author
time
two
iga
commerci
serolog
test
use
elisa
kit
laboratori
elisa
kit
laboratori
prompt
widespread
evalu
compar
variou
commerci
avail
elisa
kit
complement
fixat
cf
iga
immunofluores
iga
western
blot
wb
kit
nineti
healthi
adult
clinic
histori
respiratori
ill
preced
week
neg
cf
wb
form
neg
group
evalu
posit
group
consist
children
adult
clinic
histori
pertussi
less
week
durat
posit
cf
wb
respect
antigen
sensit
specif
commerci
iga
elisa
kit
follow
cidm
laboratori
test
serum
sampl
pertussi
iga
use
elisa
kit
follow
evalu
variou
commerci
test
sampl
retest
found
falseposit
falseposit
specimen
react
fha
antigen
band
suggest
pt
would
better
choic
elisa
antigen
howev
kit
use
pt
antigen
perform
poorli
emphas
need
better
standard
addit
group
neg
sampl
test
esen
igg
elisa
use
euml
cutoff
sampl
igg
level
unit
would
interpret
evid
recent
infect
clearli
individu
symptomat
highlight
need
caution
determin
cutoff
recent
infect
adult
particularli
highli
vaccin
popul
gener
diagnost
laboratori
prefer
commerci
avail
assay
two
studi
far
evalu
select
commerci
avail
elisa
b
pertussi
serolog
et
al
use
pair
sera
patient
children
sera
vaccine
interlaboratori
comparison
sampl
refer
prepar
schelleken
et
al
use
pair
sera
pcrposit
patient
median
age
year
control
patient
respiratori
symptom
median
age
year
anoth
studi
variou
current
exist
serolog
test
ongo
result
expect
avail
earli
summari
b
pertussi
serodiagnosi
still
suffer
mani
unsolv
problem
diagnost
test
perform
immunolog
nonnaiv
popul
antigen
compon
ap
vaccin
gener
anamnest
immun
respons
develop
rapidli
symptom
immun
respons
vaccin
antigen
distinguish
respons
infect
problem
also
exist
serodiagnosi
b
parapertussi
infect
serolog
interpret
requir
knowledg
pertussi
immun
inform
typic
known
test
laboratori
reliabl
standard
elisa
system
commerci
avail
time
addit
clinic
cours
appear
differ
primari
nonprimari
infect
subject
clinic
case
definit
pertussi
remain
nonspecif
current
suitabl
serolog
test
recent
vaccin
patient
sinc
test
base
nonvaccin
antigen
satisfactori
diagnosi
final
use
singlesampl
serolog
populationbas
cutoff
need
reverif
chang
made
vaccin
schedul
discuss
focus
use
antigen
present
vaccin
serolog
diagnosi
pertussi
cherri
et
al
show
patient
vaccin
failur
respond
poorli
act
antigen
suggest
induc
toler
due
phenomenon
call
origin
antigen
sin
phenomenon
vaccin
patient
respond
antigen
prime
respond
new
antigen
eg
act
associ
infect
therefor
suggest
nonvaccin
antigen
may
good
pt
serolog
diagnosi
pertussi
vaccin
popul
point
discuss
includ
potenti
use
revers
vaccinolog
approach
identifi
new
antigen
candid
use
serolog
diagnost
lack
specif
antigen
pt
fha
act
lack
sensit
specif
commerci
test
current
avail
worldwid
broadli
discuss
point
one
commerci
igg
iga
antipt
test
avail
unit
state
standard
provid
adequ
sensit
specif
diagnosi
pertussi
person
older
year
age
present
jame
cherri
studi
wholecel
pertussi
vaccin
agglutinin
titer
greater
found
protect
pertussi
children
expos
within
household
agglutin
antibodi
thought
primarili
direct
agglutinogen
prn
lipopolysaccharid
two
nine
ap
vaccin
efficaci
trial
conduct
done
way
data
relat
serolog
correl
could
develop
trial
center
erlangen
germani
stockholm
sweden
determin
serolog
correl
antibodi
titer
specif
antigen
determin
time
exposur
studi
indic
prn
import
protect
antibodi
fim
next
import
also
note
studi
appar
antagon
antibodi
pt
fim
clinic
trial
children
mild
sever
diseas
includ
analys
efficaci
jump
consider
vaccin
contain
prn
well
pt
fha
compar
pt
ptfha
vaccin
erlangen
trial
imput
titer
time
exposur
dtp
dtap
vaccin
failur
examin
major
failur
subject
high
level
antibodi
prn
difficult
explain
relat
overal
data
serolog
correl
indic
much
yet
learn
serolog
correl
interest
fact
dtwp
vaccin
evan
vaccin
compar
twocompon
dtap
vaccin
threecompon
dtap
vaccin
fivecompon
dtap
vaccin
greatest
efficaci
note
dtwp
vaccin
vaccin
elicit
minim
antibodi
respons
pt
fha
euml
respect
high
valu
prn
fim
euml
respect
discuss
center
diagnos
pertussi
serolog
use
antigen
contain
vaccin
antigen
contain
vaccin
although
still
controversi
acutephas
serum
collect
earli
titer
increas
vaccin
antigen
nonvaccin
antigen
use
diagnosi
discuss
relat
cellmedi
respons
associ
infect
use
anim
model
studi
infect
consider
addit
antigen
might
includ
vaccin
present
john
b
robbin
md
nation
institut
health
bethesda
maryland
us
dr
robbin
present
evid
support
hypothesi
base
classic
articl
pittman
inactiv
immunogen
pertussi
toxoid
ptox
essenti
suffici
pertussi
vaccin
furthermor
discuss
data
suggest
multicompon
pertussi
vaccin
includ
nonprotect
antigen
may
difficult
standard
us
pertussi
case
report
cdc
increas
despit
high
immun
rate
among
infant
children
booster
dose
start
adolesc
offer
everi
year
maintain
high
level
immun
popul
dr
robbin
recommend
genet
inactiv
toxin
replac
chemic
inactiv
toxoid
mass
immun
infant
adolesc
adult
respect
goal
meet
import
assay
measur
serum
pt
igg
emphas
pt
igg
reliabl
assay
serolog
diagnosi
pertussi
acut
phase
pertussi
pass
concentr
vaccineinduc
igg
antipt
correl
efficaci
monocompon
ptox
correl
indic
level
igg
antipt
may
predict
efficaci
ap
vaccin
number
particip
rais
question
relat
hypothesi
ptox
alon
suffici
pertussi
vaccin
mention
studi
support
hypothes
includ
serolog
studi
includ
serolog
one
show
evid
addit
fha
vaccin
provid
protect
infect
data
includ
report
base
extens
investig
sweden
present
meet
supplement
present
rosemari
carlsson
md
swedish
institut
infecti
diseas
control
contradict
mani
conclus
present
session
particip
also
question
appropri
analog
diphtheria
ptox
present
pathogenesi
immun
well
present
correl
protect
meet
also
varianc
hypothesi
ptox
alon
suffici
pertussi
vaccin
discuss
cut
short
allow
adequ
time
consider
issu
relat
assay
standard
main
focu
meet
conclus
previous
reach
whoconven
work
group
clinic
evalu
new
ap
vaccin
serv
introduct
discuss
one
conclus
addit
placebocontrol
protect
efficaci
studi
feasibl
sinc
withhold
pertussi
vaccin
longer
possibl
rel
efficaci
studi
adequ
size
statist
power
also
seem
unlik
approv
new
ap
vaccin
would
reli
compar
immunogen
data
apcontain
vaccin
licens
thu
far
unit
state
european
union
incorpor
pertussi
antigen
made
manufacturerspecif
process
includ
least
one
success
vaccin
efficaci
trial
infant
therefor
immunogen
data
use
link
demonstr
efficaci
test
ap
vaccin
new
ap
vaccin
even
total
antigen
composit
two
vaccin
differ
comparison
immun
respons
new
refer
apcontain
vaccin
rais
sever
difficult
question
exampl
identifi
immunolog
correl
protect
pertussi
known
antigen
elicit
immun
respons
import
prevent
clinic
appar
infect
also
known
whether
primari
comparison
term
percentag
postvaccin
titer
assay
cutoff
seroconvers
rate
open
variou
definit
geometr
mean
antibodi
titer
whichev
immunolog
paramet
chosen
primari
comparison
difficult
decid
might
constitut
clinic
import
differ
addit
predefin
criteria
noninferior
might
met
one
immunolog
paramet
unknown
implic
protect
uncertainti
overal
judgment
like
protect
efficaci
apcontain
vaccin
take
account
aspect
immun
respons
thu
immunogen
data
describ
term
percentag
subject
reach
assay
cutoff
percentag
achiev
fourfold
increment
antibodi
concentr
similar
definit
seroconvers
geometr
mean
antibodi
titer
revers
cumul
distribut
uncertainti
regard
predict
valu
immunolog
comparison
support
import
postlicensur
surveil
program
assess
effect
ap
vaccin
pertussi
diseas
howev
unlik
vaccinespecif
estim
effect
could
gener
sinc
would
requir
data
region
countri
vaccin
use
contain
ap
antigen
manufactur
complex
program
infrastructur
need
gener
reliabl
data
diseas
data
like
come
surveil
conduct
public
health
agenc
futur
new
apcontain
vaccin
might
includ
rang
ap
antigen
previous
shown
efficaci
may
made
differ
manufactur
andor
differ
process
new
apcontain
vaccin
could
also
differ
composit
pertussi
antigen
type
andor
amount
compar
vaccin
previous
evalu
protect
efficaci
agre
regulatori
posit
minim
data
would
requir
support
approv
product
howev
practic
limit
point
need
consid
immunogen
data
could
best
use
provid
reassur
regard
like
efficaci
new
apcontain
vaccin
contain
antigen
includ
least
one
vaccin
evalu
previou
protect
efficaci
studi
immun
respons
could
compar
new
vaccin
approv
vaccin
similar
ap
antigen
content
new
apcontain
vaccin
contain
fewer
antigen
differ
amount
antigen
andor
addit
antigen
vaccin
previous
shown
provid
protect
efficaci
need
care
justif
differ
new
past
efficaci
vaccin
would
like
base
nonclin
studi
particular
respons
pt
compon
fulli
assess
efficaci
anim
model
estim
function
antibodi
pt
exampl
use
cho
cell
neutral
assay
puriti
integr
function
activ
antigen
assess
physicalchem
evalu
measur
residu
toxic
applic
assess
immunogen
base
bind
function
assay
protect
effect
relev
begin
brief
overview
pertussi
vaccin
evalu
unit
state
ap
vaccin
first
licens
toddler
infant
adult
adolesc
serolog
respons
ap
vaccin
use
measur
lottolot
clinic
consist
bridg
popul
evalu
booster
immun
new
combin
concomit
vaccin
relev
paramet
measur
includ
geometr
mean
concentr
well
percentag
respond
addit
revers
cumul
distribut
curv
prove
inform
way
display
serolog
respons
data
composit
formul
ap
vaccin
vari
wide
manufactur
product
global
accept
refer
prepar
releas
criteria
establish
thu
current
refer
materi
releas
criteria
productspecif
caus
difficulti
standard
laboratori
test
control
vaccin
basi
current
regulatori
approach
demonstr
newli
manufactur
lot
compar
either
lot
shown
accept
clinic
trial
perform
lot
consid
equival
clinic
trial
lot
current
routin
control
test
ap
vaccin
includ
character
antigen
assay
immunogen
assay
residu
pt
bioactiv
histamin
sensit
test
ident
test
antigen
compon
modifi
intracerebr
challeng
assay
mica
modifi
kendrick
test
use
japan
korea
china
potenc
assay
releas
specif
unitdos
vaccin
regul
use
approach
shown
effect
control
pertussi
countri
nation
defin
offici
potenc
test
use
present
immunogen
test
use
monitor
consist
product
routin
control
procedur
comparison
clinic
trial
lot
equival
howev
criteria
evalu
equival
must
defin
defin
common
specif
set
recent
evid
suggest
antibodi
cellmedi
immun
contribut
protect
process
variabl
extent
follow
decis
made
ad
hoc
work
group
meet
nibsc
uk
intern
collabor
studi
protect
model
ap
vaccin
initi
outcom
studi
discuss
subsequ
work
group
meet
harmon
procedur
intranas
challeng
assay
inca
defin
shown
effect
monitor
activ
differ
vaccin
transfer
laboratori
futur
work
optim
experiment
condit
allow
calcul
rel
potenc
need
refer
vaccin
need
agre
upon
model
use
develop
character
new
product
formul
perform
preclin
evalu
stabil
lot
consist
monitor
current
safeti
test
ap
vaccin
includ
assay
residu
activ
pt
revers
detoxif
base
histamin
sensit
activ
endotoxin
assay
gener
toxic
test
absenc
toxin
signific
level
heatlabil
toxin
act
tracheal
cytotoxin
control
process
valid
problem
associ
histamin
sensit
test
includ
variat
test
perform
among
laboratori
absenc
intern
defin
accept
criterion
assay
influenc
signific
interact
pt
vaccin
compon
histamin
sensit
assay
unknown
assay
could
improv
defin
assay
sensit
includ
refer
group
narrow
rang
permiss
sensit
express
result
intern
unit
iu
pt
activ
rel
common
refer
establish
limit
base
panel
product
known
safeti
histori
summari
current
qualiti
control
test
specif
ap
vaccin
productspecif
clinic
relev
approach
remain
uncertain
effect
potenc
assay
new
product
formul
defin
suitabl
refer
prepar
identifi
current
histamin
sensit
test
upper
limit
activ
residu
pt
defin
use
refer
prepar
encourag
final
specif
assay
residu
activ
pt
requir
use
anim
identifi
challeng
test
apbas
combin
vaccin
still
remain
immunolog
evalu
dtap
combin
coadministr
dtapbas
vaccin
gsk
refer
back
origin
dtap
efficaci
trial
cornerston
comparison
among
combin
vaccin
separ
administ
licens
counterpart
evalu
antibodi
respons
pt
fha
prn
noninferior
percentag
vaccin
respond
well
geometr
mean
titer
form
basi
licensur
new
combin
coadministr
revers
cumul
antibodi
distribut
curv
also
use
comparison
character
new
dtap
combin
gsk
involv
evalu
clinic
tcell
respons
well
preclin
evalu
mous
lung
clearanc
model
respect
vaccin
composit
protect
avail
data
suggest
potent
dtwp
dtap
contain
pt
prn
induc
high
level
protect
whoop
cough
mechan
link
prnmediat
protect
relat
observ
prn
express
affect
act
activ
induc
opsonophagocyt
antibodi
dtap
efficaci
trial
contradictori
regard
efficaci
pt
fha
without
prn
initi
efficaci
report
seneg
accord
criteria
later
correct
sinc
origin
diagnost
criteria
differ
trial
efficaci
seneg
probabl
similar
efficaci
observ
anoth
sweden
find
pt
immun
respons
seneg
time
higher
western
europ
conclus
dtwp
dtap
compon
prefer
option
immun
whoop
cough
demonstr
efficaci
compar
although
uncertain
protect
antigen
durat
protect
dtwp
dtap
estim
year
control
pertussi
newborn
adolesc
adult
dtap
booster
immun
recommend
sanofi
pasteur
use
immunoassay
b
pertussi
igg
elisa
pt
fha
prn
fim
antigen
support
evalu
vaccineinduc
immun
respons
assay
use
essenti
identifi
manclark
et
al
key
reagent
qualifi
standard
coat
antigen
highli
purifi
assess
physic
chemistri
immunolog
method
ensur
puriti
antigen
specif
assay
refer
sera
bridg
intern
refer
perform
demonstr
remain
stabl
control
sera
shown
specif
repres
suitabl
rang
across
rang
assay
compon
qualifi
perform
panel
sera
ensur
consist
assay
fulli
valid
precis
interand
intralaboratori
accuraci
use
spike
recoveri
specif
assess
matrix
effect
perform
competit
studi
linearitydilut
limit
detect
lod
limit
quantit
loq
robust
perspect
vaccin
manufactur
sanofi
pasteur
issu
concern
task
global
standard
focu
critic
reagent
data
reduct
method
coat
antigen
consider
need
given
impact
antigen
sourc
well
criteria
qualiti
consumpt
rate
refer
laboratori
forc
develop
intern
refer
bridg
intern
standard
guidanc
need
best
select
intern
refer
sustain
intern
refer
support
frequent
calibr
similarli
guidanc
need
best
characterist
control
implement
qualiti
control
assay
accept
criteria
final
data
reduct
guidanc
need
establish
data
reduct
system
suitabl
today
laboratori
chairperson
freyja
lynn
bs
nation
institut
allergi
infecti
diseas
nation
institut
health
bethesda
maryland
us
annett
morri
bs
bed
canadian
center
vaccinolog
dalhousi
univers
nova
scotia
canada
achiev
harmon
assay
clinic
diagnosi
pertussi
evalu
immun
postvaccin
sever
issu
address
first
consensu
methodolog
assay
valid
analysi
result
requir
facilit
comparison
among
data
gener
differ
laboratori
requir
diagnost
assay
like
differ
aspect
assay
use
perform
postvaccin
immun
evalu
stabil
assay
result
time
depend
consist
avail
appropri
character
reagent
materi
studi
requir
determin
effect
assay
result
differ
sourc
lot
antigen
conjug
reagent
profici
panel
human
sera
vital
harmon
method
laboratori
although
creat
panel
suffici
volum
worldwid
use
challeng
refer
laboratori
seri
connect
refer
laboratori
essenti
resourc
methodolog
chang
control
manag
evalu
profici
panel
final
repositori
distribut
standard
materi
antigen
conjug
refer
materi
crucial
standard
harmon
b
pertussi
assay
steer
committe
establish
purpos
identifi
priorit
step
toward
harmon
includ
identif
resourc
requir
implement
harmon
accomplish
must
global
effort
collabor
mani
research
govern
corpor
organ
current
evalu
collabor
studi
propos
intern
refer
prepar
human
pertussi
antiserum
shown
accept
avail
intern
refer
materi
valuabl
promot
harmon
addit
collabor
studi
data
avail
provid
inform
compar
result
particip
laboratori
help
point
prioriti
focus
action
item
accomplish
standard
harmon
b
pertussi
immunoassay
identifi
group
discuss
includ
follow
identifi
group
organ
prepar
maintain
distribut
common
pertussi
perform
serum
profici
panel
use
help
laboratori
develop
assay
monitor
stabil
assembl
work
group
assist
detail
panel
encourag
develop
identif
one
refer
laboratori
serv
anchor
resourc
laboratori
focu
key
reagent
refer
control
sera
defin
performancebas
assay
method
serv
refer
point
evalu
laboratori
differ
develop
guidanc
qualiti
reagent
eg
pt
antigen
method
demonstr
suitabl
establish
intern
work
group
harmon
criteria
evalu
result
obtain
refer
profici
panel
sera
creat
inventori
determin
amount
appropri
wellcharacter
sera
avail
global
use
bridg
reagent
vaccin
licensur
seek
specif
guidanc
regulatori
author
regard
expect
requir
licensur
new
multicompon
pertussi
vaccin
